NCT03209479Completed
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
Source: ClinicalTrials.gov · Last updated 13 Jun 2024
Brief summary (registry, in English)
The purpose of this study is to evaluate the safety and efficacy of Copaxone subcutaneous injection syringe (hereinafter referred to as Copaxone) in patients with multiple sclerosis in the routine clinical setting.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1332 (actual)
- First submitted
- 4 Jul 2017
- Start date
- 24 Nov 2015
- Primary completion date
- 31 Mar 2024
- Lead sponsor
- Teva Takeda Pharma Ltd.
- Diseases
- Multiple sclerosis
- NCT number
- NCT03209479
What you commit to
- Study type: Observational
- Participants enrolled: 1332
- From 24 Nov 2015 to the primary completion date, 31 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- -None
Who the study is looking for
- \- All patients treated with Copaxone from the first day of market launch of the product
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Takeda Selected Site Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.